Background:
Many transgender men and non-binary (TMNB) people receiving gender-affirming care take synthetic testosterone as part of their masculinizing hormone therapy (MHT) regimen. This population is disproportionately affected by HIV and other sexually transmitted infections (STIs). Testosterone is known to have immunosuppressive activity and may modulate HIV/STI susceptibility. Yet little is known about the immunological characteristics of the vaginal mucosa in people assigned female at birth (AFAB) on MHT. Our objective in this study was to characterize the vaginal immune microenvironment of AFAB TMNB individuals on MHT to provide baseline immunological knowledge and guide future research.
Methods:
We recruited 72 AFAB participants from the Washington, DC metro area (aged 18-44, sexually active, HIV-negative) and conducted a cross-sectional study comparing 36 TMNB participants who had been on MHT for at least six months with a control group of 36 cisgender/non-binary participants not on MHT. Participants provided clinical and demographic data and self-collected vaginal swabs. The concentrations of a panel of inflammatory and antimicrobial immune biomarkers in samples were assessed by ELISA. Statistical analyses were performed using Mann-Whitney U tests to compare biomarker values between the MHT and non-MHT groups (GraphPad Prism 10.0.2).
Results:
Compared to non-MHT controls, the MHT group had significantly elevated levels of inflammatory biomarkers Myeloperoxidase (p=0.0101), TNFα (p=0.0053), and MIP1α (p<0.0001). The MHT group also had significantly lower levels of antimicrobial biomarkers Elafin (p<0.001), SLPI (p=0.0085), and Human Beta-Defenisn-2 (p=0.0033) compared to the control group. Age, race, income, hormonal contraceptive use, and sexual behavior were similar between the groups.
Conclusions:
We found evidence of vaginal immune dysregulation in TMNB individuals receiving MHT. Dysregulation of inflammatory and antimicrobial biomarkers is a potential underlying mechanism that can affect HIV/STI susceptibility. Our findings add to the scant body of knowledge available on the immunomodulatory effects of synthetic testosterone in the vagina and may inform future studies on sexual health in TMNB. Our findings do not negate MHT as a clinically safe standard of care in TMNB, but point to an indication for integrating HIV/STI prevention services into gender-affirming care programs for individuals on MHT.